{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:55:00Z","timestamp":1783590900715,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier","isbn-type":[{"value":"9780128177389","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.pmbts.2018.12.012","type":"book-chapter","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T02:52:39Z","timestamp":1551840759000},"page":"241-252","source":"Crossref","is-referenced-by-count":31,"title":["Serum CA125 levels are decreased in rectal cancer but increased in fibrosis-associated diseases and in most types of cancers"],"prefix":"10.1016","author":[{"given":"Meng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/bs.pmbts.2018.12.012_bb0010","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma","volume":"68","author":"Bast","year":"1981","journal-title":"J Clin Invest"},{"issue":"5517","key":"10.1016\/bs.pmbts.2018.12.012_bb0015","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"issue":"5","key":"10.1016\/bs.pmbts.2018.12.012_bb0020","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1525-1438.2005.00130.x","article-title":"CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use","volume":"15","author":"Duffy","year":"2005","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.012_bb0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bpj.2011.11.4010","article-title":"Coarse-grained modeling of mucus barrier properties","volume":"102","author":"Gniewek","year":"2012","journal-title":"Biophys J"},{"issue":"29","key":"10.1016\/bs.pmbts.2018.12.012_bb0030","doi-asserted-by":"crossref","first-page":"27371","DOI":"10.1074\/jbc.M103554200","article-title":"Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16","volume":"276","author":"Yin","year":"2001","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/bs.pmbts.2018.12.012_bb0035","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ijc.10250","article-title":"Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene","volume":"98","author":"Yin","year":"2002","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/bs.pmbts.2018.12.012_bb0040","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000050637","article-title":"CA 125: the end of the beginning","volume":"22","author":"Hovig","year":"2001","journal-title":"Tumour Biol"},{"issue":"3","key":"10.1016\/bs.pmbts.2018.12.012_bb0045","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ygyno.2005.07.030","article-title":"Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125","volume":"99","author":"Patankar","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"pt 7","key":"10.1016\/bs.pmbts.2018.12.012_bb0050","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1242\/jcs.00312","article-title":"The cancer antigen CA125 represents a novel counter receptor for galectin-1","volume":"116","author":"Seelenmeyer","year":"2003","journal-title":"J Cell Sci"},{"issue":"3","key":"10.1016\/bs.pmbts.2018.12.012_bb0055","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ygyno.2011.02.020","article-title":"MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis","volume":"121","author":"Theriault","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/bs.pmbts.2018.12.012_bb0060","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol Cancer"},{"issue":"10","key":"10.1016\/bs.pmbts.2018.12.012_bb0065","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/bs.pmbts.2018.12.012_bb0070","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/172460089801300402","article-title":"CA 125: the past and the future","volume":"13","author":"Bast","year":"1998","journal-title":"Int J Biol Markers"},{"issue":"1","key":"10.1016\/bs.pmbts.2018.12.012_bb0075","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1183\/09031936.00094206","article-title":"Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax","volume":"31","author":"Bagan","year":"2008","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/bs.pmbts.2018.12.012_bb0080","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ajog.2008.04.009","article-title":"The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?","volume":"199","author":"Nossov","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.012_bb0085","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/10408360601003143","article-title":"Tumor markers in biological fluids associated with pregnancy","volume":"44","author":"Sarandakou","year":"2007","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.012_bb0090","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1245\/ASO.2003.05.015","article-title":"Cancer antigen 125 associated with multiple benign and malignant pathologies","volume":"10","author":"Miralles","year":"2003","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.012_bb0095","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2005.06.040","article-title":"Potential markers that complement expression of CA125 in epithelial ovarian cancer","volume":"99","author":"Rosen","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/bs.pmbts.2018.12.012_bb0100","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2217\/bmm.09.21","article-title":"Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?","volume":"3","author":"Sasaroli","year":"2009","journal-title":"Biomark Med"},{"issue":"6","key":"10.1016\/bs.pmbts.2018.12.012_bb0105","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000050638","article-title":"The CA 125 gene: an extracellular superstructure dominated by repeat sequences","volume":"22","author":"O'Brien","year":"2001","journal-title":"Tumour Biol"},{"key":"10.1016\/bs.pmbts.2018.12.012_bb0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1757-2215-2-13","article-title":"Role of CA125 in predicting ovarian cancer survival\u2014a review of the epidemiological literature","volume":"2","author":"Gupta","year":"2009","journal-title":"J Ovarian Res"},{"issue":"15","key":"10.1016\/bs.pmbts.2018.12.012_bb0115","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer","volume":"309","author":"Bast","year":"1983","journal-title":"N Engl J Med"},{"issue":"12 pt 1","key":"10.1016\/bs.pmbts.2018.12.012_bb0120","first-page":"6143","article-title":"Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas","volume":"46","author":"Davis","year":"1986","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/bs.pmbts.2018.12.012_bb0125","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000217982","article-title":"Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine","volume":"17","author":"Nustad","year":"1996","journal-title":"Tumour Biol"},{"issue":"6","key":"10.1016\/bs.pmbts.2018.12.012_bb0130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000217996","article-title":"Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop","volume":"17","author":"Nap","year":"1996","journal-title":"Tumour Biol"},{"issue":"4","key":"10.1016\/bs.pmbts.2018.12.012_bb0135","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1155\/2013\/917898","article-title":"OC125, M11 and OV197 epitopes are not uniformly distributed in the tandem-repeat region of CA125 and require the entire SEA domain","volume":"34","author":"Bressan","year":"2013","journal-title":"Dis Markers"},{"issue":"1","key":"10.1016\/bs.pmbts.2018.12.012_bb0140","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1186\/s12885-017-3738-y","article-title":"Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer","volume":"17","author":"Feng","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/bs.pmbts.2018.12.012_bb0145","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cca.2017.04.023","article-title":"The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer","volume":"470","author":"Wang","year":"2017","journal-title":"Clin Chim Acta"},{"key":"10.1016\/bs.pmbts.2018.12.012_bb0150","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2147\/CMAR.S155693","article-title":"Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/bs.pmbts.2018.12.012_bb0155","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/gyno.1996.0191","article-title":"Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor","volume":"62","author":"Tamakoshi","year":"1996","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/bs.pmbts.2018.12.012_bb0160","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/clinchem\/44.7.1379","article-title":"CA 125 in ovarian cancer: advances and controversy","volume":"44","author":"Fritsche","year":"1998","journal-title":"Clin Chem"},{"issue":"6","key":"10.1016\/bs.pmbts.2018.12.012_bb0165","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.1572-0241.1999.01152.x","article-title":"Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis","volume":"94","author":"Zuckerman","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/bs.pmbts.2018.12.012_bb0170","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00000441-198607000-00006","article-title":"Clinical significance of serum CA125 values in patients with cancers of the digestive system","volume":"292","author":"Haga","year":"1986","journal-title":"Am J Med Sci"},{"issue":"11","key":"10.1016\/bs.pmbts.2018.12.012_bb0175","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/j.1651-2227.2003.tb00495.x","article-title":"Association between serum oncofetal antigens CA 19-9 and CA 125 and clinical status in patients with cystic fibrosis","volume":"92","author":"Gronowitz","year":"2003","journal-title":"Acta Paediatr"},{"key":"10.1016\/bs.pmbts.2018.12.012_bb0180","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","article-title":"Asialoglycoprotein receptor mediated hepatocyte targeting\u2014strategies and applications","volume":"203","author":"D'Souza","year":"2015","journal-title":"J Control Release"},{"issue":"7","key":"10.1016\/bs.pmbts.2018.12.012_bb0185","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1074\/jbc.M210612200","article-title":"Rapid clearance of sialylated glycoproteins by the asialoglycoprotein receptor","volume":"278","author":"Park","year":"2003","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.012_bb0190","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/0014-5793(92)80373-O","article-title":"The clearance of apoptotic cells in the liver is mediated by the asialoglycoprotein receptor","volume":"296","author":"Dini","year":"1992","journal-title":"FEBS Lett"},{"issue":"12","key":"10.1016\/bs.pmbts.2018.12.012_bb0195","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","article-title":"An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study","volume":"5","author":"Maher","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/bs.pmbts.2018.12.012_bb0200","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1541-7786.MCR-12-0274","article-title":"Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma","volume":"10","author":"van der Horst","year":"2012","journal-title":"Mol Cancer Res"},{"issue":"10","key":"10.1016\/bs.pmbts.2018.12.012_bb0205","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ncb3611","article-title":"Cell plasticity in epithelial homeostasis and tumorigenesis","volume":"19","author":"Varga","year":"2017","journal-title":"Nat Cell Biol"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.012_bb0210","doi-asserted-by":"crossref","first-page":"G102","DOI":"10.1152\/ajpgi.00452.2016","article-title":"Emerging concepts in biliary repair and fibrosis","volume":"313","author":"Fabris","year":"2017","journal-title":"Am J Physiol Gastrointest Liver Physiol"}],"container-title":["Progress in Molecular Biology and Translational Science","Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117318301601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117318301601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T07:49:28Z","timestamp":1606636168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117318301601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128177389"],"references-count":41,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2018.12.012","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}